Group 1 - The core focus of the company is on the development of Barzol for chronic spontaneous urticaria (CSU), with Phase III clinical trials expected to complete patient enrollment by July 2026 [1] - The company plans to announce Phase II data for nodular prurigo and atopic dermatitis in 2026, and advance the validation study of the bispecific platform CDX622 for severe asthma [1] Group 2 - The stock price has shown a downward trend over the past week, with a cumulative decline of 3.20% and a volatility of 11.49% [2] - On February 9, the stock rose by 4.42% to $24.81, but subsequently fell by 4.19% on February 12 and continued to decline by 2.42% to $23.00 on February 13, with trading volume increasing to $27.31 million on February 13 [2] - The biotechnology sector increased by 1.32% during the same period, but the company's performance diverged from the sector, while the Nasdaq index decreased by 0.22% [2] Group 3 - In February 2026, 15 institutions provided ratings, with 80% giving buy or hold ratings, and the average target price set at $54.54, indicating significant upside potential compared to the current price [3] - The company is still in a research investment phase, with an expected earnings per share of -$1.009 for Q4 2025, but long-term focus remains on the clinical progress of Barzol and other pipeline candidates [3]

Company Project Progress - Barzol drug Phase III clinical trial is expected to complete patient enrollment by July 2026, which is considered the most important event of the year by management. The company also plans to initiate evaluations for new indications such as food allergies and allergic rhinitis [1] - The company plans to announce Phase II clinical trial results for nodular prurigo and atopic dermatitis in 2026, which will be used to determine the dosing regimen for subsequent registration studies [1] - Updates on the bispecific project CDX622 are expected in the third quarter of 2026, with results from a subcutaneous single-dose escalation study also planned for release within the year. Based on these data, the company intends to initiate mechanism validation studies for severe asthma [1] Strategic Advancement - The company is focused on validating its bispecific platform (CDX622) and promoting Barzol as the preferred drug in the field of CSU and other diseases. For commercialization, the company plans to independently advance in the U.S. market while considering partnerships for markets outside the U.S. [2] Institutional Perspectives - On January 7, 2026, Celldex Therapeutics' stock price surged by 5.18%, with 80% of brokerage firms giving a buy recommendation. However, it is important to note that the company is still in the research and development phase, with the latest financial report showing zero revenue and a negative net profit [3]

Core Viewpoint - Cedars Medical (CLDX.US) has announced its key R&D plans for 2026, focusing on multiple clinical trial advancements and platform validation [1] Project Advancement - The Phase III clinical trial for CSU: The main drug Barzol targeting chronic spontaneous urticaria (CSU) is expected to complete patient enrollment by July 2026, which is the most anticipated event by management [2] - Update on the bispecific project CDX622: Data from the multi-dose escalation study is expected to be released in the third quarter of 2026. Results from the subcutaneous single-dose escalation study are also planned for release within 2026. The company aims to initiate mechanism validation studies for severe asthma based on these data [4] - Evaluation of new indications: The company will start assessing the potential for expanding Barzol into new indications such as food allergies and allergic rhinitis [5] Product Development Progress - Announcement of Phase II clinical data: Results from the Phase II studies on nodular prurigo and atopic dermatitis are planned for release in 2026. These studies will be used to determine the dosing regimen for subsequent registration studies [3] Strategic Advancement - Mid to long-term strategic focus: The company is committed to validating its bispecific platform (CDX622) and promoting Barzol as the preferred drug in the CSU and other disease areas. In terms of commercialization, the plan is to independently advance in the U.S. market while considering partnerships for markets outside the U.S. [6]